The relevance of prothrombotic genetic variants in women who experienced pregnancy loss or embryo implantation failure: A retrospective analysis of 1922 cases

Abstract

AbstractObjectiveThe aim of our study was that to assess the allelic and genotype frequencies of nine prothrombotic gene variants in patients with a history of pregnancy loss and recurrent pregnancy loss (RPL). Women who underwent assisted reproductive technology (ART) with ongoing pregnancy and those with recurrent implantation failure (RIF) were also included.MethodsNine prothrombotic gene variants were evaluated: factor V Leiden (FVL), factor V, H1299R variant (FVR2), factor II (FII) G20210A, methylene‐tetrahydrofolate reductase (MTHFR) C677T and A1298C, beta‐fibrinogen ‐455G>A, factor XIII (FXIII) V34L, human platelet antigen‐1 (HPA‐1) L33P variants, and plasminogen activator inhibitor‐1 (PAI‐1) 4G/5G. The following study groups were assessed: (1) women who experienced one (n = 334) or two (n = 264) episodes of pregnancy loss; (2) 468 women who experienced RPL; (3) 214 women who underwent ART followed by ongoing pregnancies; and (4) 282 women who experienced RIF after ART, that is, three or more consecutive implantation failures following high‐quality embryo transfers to the uterus with an appropriate endometrium. As control group, 430 subjects from the general population were enrolled.ResultsFVL, the ‐455G>A variant of beta‐fibrinogen, and PAI‐1 4G were associated with a higher risk of developing RPL compared with the general population. Furthermore, FVL, FVR2, FII G20210A and MTHFR C677T conferred a significantly higher risk of RIF in women who performed ART compared with the general population. No statistical differences between the general population and other study groups were observed.ConclusionsSpecific prothrombotic genetic variants are more frequently expressed in women with RPL and RIF, supporting their role in the development of polimicrothrombosis and impairing the invasion during embryo implantation.